Hemophilia is a rare genetic disorder that affects the blood's ability to clot properly. For families carrying the gene for hemophilia, the prospect of passing this condition to their children can be a source of significant concern. Fortunately, advancements in assisted reproductive technology (ART) have made it possible to significantly reduce this risk. Through IVF with PGT-M (Preimplantation Genetic Testing for Monogenic disorders), couples can select embryos that are free from the hemophilia mutation before pregnancy begins.
At our clinic in Istanbul, Turkey, we specialize in helping international patients navigate the complexities of genetic screening to ensure a healthy start for their future children.
Understanding Hemophilia and Genetic Inheritance
Hemophilia, primarily Hemophilia A and B, is an X-linked recessive disorder. This means the gene responsible for the condition is located on the X chromosome. Because males have one X and one Y chromosome, inheriting a single defective X chromosome results in the disease. Females, having two X chromosomes, are typically "carriers" if one gene is mutated, though they may occasionally show mild symptoms.
For a carrier mother, there is a 50% chance with each pregnancy that a son will have hemophilia and a 50% chance that a daughter will be a carrier. IVF combined with genetic testing allows parents to break this cycle of inheritance.
What is PGT-M?
PGT-M stands for Preimplantation Genetic Testing for Monogenic (single-gene) disorders. Unlike PGT-A, which screens for general chromosomal abnormalities like Down syndrome, PGT-M is a highly specific test designed to identify a particular genetic mutation known to run in a family.
In the case of hemophilia, the process involves creating a unique "probe" or genetic map based on the DNA of the parents and sometimes other family members. This probe is then used to test the embryos created during the IVF cycle.
The Process of IVF with PGT-M for Hemophilia
The journey toward a healthy pregnancy involves several meticulous steps, combining standard IVF procedures with high-tech laboratory diagnostics.
1. Genetic Counseling and Probe Preparation
Before treatment begins, couples meet with genetic counselors to review their medical history. DNA samples (usually via blood tests or cheek swabs) are taken from the parents to build the custom PGT-M test. This preparation phase can take several weeks.
2. Ovarian Stimulation and Egg Retrieval
The mother undergoes a hormonal stimulation protocol to produce multiple eggs. These eggs are then retrieved through a minor surgical procedure performed under sedation.
3. Fertilization via ICSI
To ensure accuracy in genetic testing, eggs are fertilized using Intracytoplasmic Sperm Injection (ICSI). This method prevents "DNA contamination" from multiple sperm, which is essential for the precision of PGT-M.
4. Embryo Biopsy and Testing
Once the embryos reach the blastocyst stage (usually day 5 or 6), a few cells are carefully removed from the trophectoderm (the part that becomes the placenta). These cells are analyzed in the genetics lab using the custom probe to identify which embryos carry the hemophilia mutation.
5. Embryo Transfer
Only embryos identified as being free of the hemophilia mutation (or, in some cases, female carriers, depending on the parents' choice) are selected for transfer into the uterus. Remaining healthy embryos can be cryopreserved for future use.
Success Rates and Considerations
The success of IVF with PGT-M depends on various individual factors, including maternal age, ovarian reserve, and the number of healthy embryos available after genetic screening. While PGT-M is highly accurate (often exceeding 98%), no test is 100% definitive. Therefore, prenatal diagnostic tests like amniocentesis are still recommended during pregnancy for confirmation.
Why Choose Istanbul for Hemophilia Genetic Screening?
Turkey has emerged as a global leader in reproductive medicine, particularly for genetic screening. Patients choose Istanbul for several reasons:
- Advanced Genetic Laboratories: Our facilities utilize the latest NGS (Next-Generation Sequencing) technology for PGT-M.
- Expertise: Our clinicians have extensive experience managing complex genetic cases and high-risk pregnancies.
- Affordability: The cost of IVF in Turkey is significantly more accessible than in the US or UK, without compromising on the quality of care or laboratory standards.
- Comprehensive Care: From the initial genetic consultation to the final embryo transfer, we provide a supportive, end-to-end experience for international patients.
Frequently Asked Questions
Can PGT-M eliminate hemophilia from my family line?
PGT-M allows for the selection of embryos that do not carry the hemophilia mutation. By transferring only these embryos, the child born from that cycle will not have the disease and, if they are not carriers, they cannot pass the mutation to future generations. However, success depends on the availability of healthy embryos from the IVF cycle.
Is the embryo biopsy safe?
The biopsy is performed at the blastocyst stage by highly skilled embryologists. Research indicates that a correctly performed biopsy does not significantly impact the embryo's ability to implant or develop into a healthy baby. The procedure is a standard part of modern genetic screening in IVF.
How long does the entire process take in Turkey?
The probe preparation phase takes about 4-6 weeks. Once the probe is ready, the IVF cycle itself takes about 3 weeks. Many international patients choose to stay in Istanbul for the duration of the stimulation and retrieval, while others coordinate the initial steps with their local doctors.